用于鉴别HMG-CoA还原酶制剂的以酵母细胞为基础的新的高通量筛选平台和该抑制剂的用途
It introduces methods of screening, identifying and isolating HMG-CoAR inhibitors. In particular, said method is useful for screening natural raw products. It also provides potent HMG-CoAR inhibitors for treatment and prevention of diseases and conditions associated with elevated cholesterol and/or blood lipid levels
High efficient, high-throughput and reproducible method for screening HMG-CoAR inhibitors
Treat and prevent diseases and conditions associated with elevated cholesterol and/or blood lipid levels
It provides a novel screening method using yeast cells and a kit to identify HMG-CoAR inhibitors. Also it provides a yeast cell-based activity-guided fractionation assay screening platform to identify and isolate HMG-CoAR inhibitors from natural products. Furthermore, it provides composition for treating and preventing diseases and conditions associated with elevated cholesterol and blood lipid level, such as hypercholesterolemia and hyperlipidemic. The present composition for treating and preventing diseases and conditions associated with elevated cholesterol and blood lipid level comprises an effective amount of an extract of Gynostemma pentaphyllum (Gp).
Patent Number: CN103243147A
Application Number: CN201310052418A
Inventor: JIANG, Zhi-hong | XIAO, Wen-luan | DAI, Zi-cheng
Priority Date: 9 Feb 2012
Priority Number: CN103243147A
Application Date: 18 Feb 2013
Publication Date: 14 Aug 2013
IPC Current: C12Q000126 | A61K0031704 | A61K0036424 | A61P000306 | C12Q000102
Assignee Applicant: Hong Kong Baptist University
Title: Novel high-throughput yeast cell-based screening platform for identifying HMG-CoA reductase inhibitors and uses of such inhibitors | A new high throughput screening platform for identifying of HMG-CoA reductase inhibitors based on yeast cell and applicati
Usefulness: Novel high-throughput yeast cell-based screening platform for identifying HMG-CoA reductase inhibitors and uses of such inhibitors | A new high throughput screening platform for identifying of HMG-CoA reductase inhibitors based on yeast cell and application of the inhibitor
Summary: For screening to identify enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR) inhibitors; in composition for treating/preventing a disease, condition associated with elevated cholesterol and/or blood lipid level (selected from hypercholesterolemia or hyperlipidemic) (all claimed).
Novelty: Screening to identify enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors involves measuring cell viability of yeast strain containing 3-hydroxy-3-methylglutaryl 1 overexpression plasmid, contacting and adding mevalonate
Biomedical
DNA/Gene Engineering
2013.02.18
CN 201310052418
Published
A61/HW/Usin/CN01
Hong Kong
